AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2021
May 1, 2021
32131_dirs_2021-04-30_de0f190c-bc01-43a0-9f0a-176cc7f9e387.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-04-28
Reporting Person: Chacko Jacob (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-28 | Common Stock | S | 700 | $25.0596 | Disposed | 61000 | Direct |
| 2021-04-30 | Common Stock | S | 600 | $25.2383 | Disposed | 60400 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Represents the weighted average share price of an aggregate total of 700 shares sold in the price range of $25.00 to $25.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 600 shares sold in the price range of $25.10 to $25.44 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.